Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 4/20 | 0.52 |
| ▸ | F2 | P00734 | 2/20 | 0.52 |
| ▸ | EDNRA | P25101 | 1/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13897354 | 1.00 | TYMS (0.52) | TYMSF2EDNRAPRSS1PRSS2 | |
| SCHEMBL179968 | 1.00 | TYMS (0.52) | TYMSF2EDNRAPRSS1PRSS2 | |
| SCHEMBL14178928 | 0.93 | TYMS (0.52) | TYMSF2EDNRAPRSS1PRSS2 | |
| SCHEMBL20645012 | 0.92 | TYMS (0.47) | TYMSF2EDNRA | |
| SCHEMBL5706271 | 0.88 | TYMS (0.54) | TYMSF2EDNRAPRSS1PRSS2 | |
| SCHEMBL6266410 | 0.88 | TYMS (0.54) | TYMSF2EDNRAPRSS1PRSS2 | |
| SCHEMBL4134777 | 0.87 | LMNA (0.57) | TYMSF2 | |
| SCHEMBL4134778 | 0.87 | LMNA (0.57) | TYMSF2 | |
| SCHEMBL180019 | 0.87 | TYMS (0.53) | TYMSF2EDNRAPRSS1PRSS2 | |
| SCHEMBL13884437 | 0.87 | TYMS (0.53) | TYMSF2EDNRAPRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149332-A1 | METHODS FOR DETERMINING THE ACTIVITY OF ADAM-TS PROTEASES USING THIOPEPTOLIDES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-06-11 | — | — | US | claimed |
| US-20040082499-A1 | Perturbed membrane-binding compounds | APOSENSE LTD. (IL) | 2004-04-29 | — | — | US | claimed |
| US-5286286-A | Containing diethylene glycol monobutyl ether, glycerol, and a dansyl or porphyrin chromophores | XEROX CORPORATION (US) | 1994-02-15 | — | — | US | claimed |
| US-10888622-B2 | Nanocomplexes of modified peptides or proteins | TRUSTEES OF TUFTS COLLEGE (US) | 2021-01-12 | — | — | US | disclosed |
| US-10301413-B2 | Mixed charge copolymers and hydrogels | UNIVERSITY OF WASHINGTON (US) | 2019-05-28 | — | — | US | disclosed |
| US-10201174-B2 | Process for reducing contaminating Michael acceptor levels in oxycodone and other compositions | CONTROLLED CHEMICALS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| EP-2424573-B1 | LABELED MOLECULAR IMAGING AGENTS, METHODS OF MAKING AND METHODS OF USE | GEN ELECTRIC (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-2069412-B1 | MIXED CHARGE COPOLYMERS AND HYDROGELS | UNIV WASHINGTON (US) | 2019-01-02 | — | — | EP | disclosed |
| US-20170027199-A1 | PROCESS FOR REDUCING CONTAMINATING MICHAEL ACCEPTOR LEVELS IN OXYCODONE AND OTHER COMPOSITIONS | CONTROLLED CHEMICALS, INC. (US) | 2017-02-02 | — | — | US | disclosed |
| US-9403838-B2 | Process for reducing contaminating Michael acceptor levels in oxycodone and other compositions | CONTROLLED CHEMICALS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160129120-A1 | NANOCOMPLEXES OF MODIFIED PEPTIDES OR PROTEINS | TRUSTEES OF TUFTS COLLEGE | 2016-05-12 | — | — | US | disclosed |
| US-20070149559-A1 | composition is treated with a thiol-containing compound under conditions sufficient to remove Michael acceptors such as 14-hydroxycodeinone | CONTROLLED CHEMICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007062184-A2 | PROCESSES FOR REDUCING CONTAMINATING MICHAEL ACCEPTOR LEVELS IN OXYCODONE AND OTHER COMPOSITIONS | CONTROLLED CHEMICALS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-7195913-B2 | Randomly ordered arrays and methods of making and using | SURMODICS, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20040082499-A1 | Perturbed membrane-binding compounds | APOSENSE LTD. (IL) | 2004-04-29 | — | — | US | disclosed |
| EP-1401420-A2 | PERTURBED MEMBRANE-BINDING COMPOUNDS | NST Neurosurvival Technologies Ltd. (IL) | 2004-03-31 | — | — | EP | disclosed |
| US-20030099949-A1 | Arrays having clustered arrangements and methods of making and using | SURMODICS, INC. | 2003-05-29 | — | — | US | disclosed |
| US-20030073086-A1 | Randomly ordered arrays and methods of making and using | SURMODICS, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2002046147-A2 | PERTURBED MEMBRANE-BINDING COMPOUNDS | NST NEUROSURVIVAL TECHNOLOGIES LTD. (IL) | 2002-06-13 | — | — | WO | disclosed |
| US-5952173-A | QUANTITATIVE OR QUALITATIVE ANALYSIS USING ANALYTICAL DEVICE FOR FLUID FLOW OF MICROVOLUMES; TEST SAMPLE IS TRANSPORTED THROUGH CHANNELS TO STRUCTURES ON BASE LAYER WITH IMMOBILIZED REAGENT CAPABLE OF BINDING ANALYTE, DETECTING BINDING SIGNAL | ABBOTT LABORATORIES (US) | 1999-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160129120-A1 | NANOCOMPLEXES OF MODIFIED PEPTIDES OR PROTEINS | LNPEP, ACP1, CRYAA | TYMS 4855/4885F2 1295/4885EDNRA 1264/4885 |
| US-20170027199-A1 | PROCESS FOR REDUCING CONTAMINATING MICHAEL ACCEPTOR LEVELS IN OXYCODONE AND OTHER COMPOSITIONS | OPRK1, OPRD1, OPRL1 | TYMS 1686/4885F2 3637/4885EDNRA 1528/4885 |
| US-10201174-B2 | Process for reducing contaminating Michael acceptor levels in oxycodone and other compositions | OPRK1, OPRD1, OPRL1 | TYMS 1686/4885F2 3637/4885EDNRA 1528/4885 |
| US-20070149559-A1 | composition is treated with a thiol-containing compound under conditions sufficient to remove Michael acceptors such as 14-hydroxycodeinone | SQOR, SHMT2, ALOX15B | TYMS 982/4885F2 2738/4885EDNRA 1687/4885 |
| US-10888622-B2 | Nanocomplexes of modified peptides or proteins | LNPEP, ACP1, CRYAA | TYMS 4855/4885F2 1295/4885EDNRA 1264/4885 |
| US-20040082499-A1 | Perturbed membrane-binding compounds | PEBP1, VAPB, MBOAT1 | TYMS 3275/4885F2 3905/4885EDNRA 4545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.